WEBULL
WebtradeDownload

IDEAYA Biosciences (IDYA) Stock May Be Pricey Despite Uveal Melanoma Drug Progress

Simply Wall St · 1d ago

IDEAYA Biosciences has delivered a 35.6% share price gain over the past 5 years, while its precision oncology pipeline has moved forward with new drug applications and late stage trial plans. That combination of stock performance and fresh clinical momentum raises a straightforward question for investors who care about balance sheet anchors: how well does today’s price line up with the company’s book value?

  • Over 5 years, IDEAYA Biosciences has returned 35.6%. That puts real weight on whether its underlying net assets and capital base are keeping pace with the market’s enthusiasm.
  • Recent progress on uveal melanoma therapy and other pipeline programs may support expectations for future revenue and funding needs, which both feed directly into how much value investors assign to the current equity cushion on the balance sheet.
  • There is a second opinion on IDEAYA Biosciences worth weighing. See what analysts think IDEAYA Biosciences's shares could be worth.

The issue now is whether IDEAYA Biosciences’ recent share price, after that multi year gain and pipeline progress, is adequately supported by its book value compared with the industry average.

If you are weighing IDEAYA Biosciences against similar opportunities, a focused stock screen built around 32 high quality undervalued stocks can be a useful second starting point for your research.

Is IDEAYA Biosciences Getting Expensive on Book Value?

P/B suits IDEAYA Biosciences because investors are still anchoring on its capital base while the business works through heavy research spending and limited current earnings.

On this metric, IDEAYA trades on a P/B of 2.8x compared with a Biotechs sector average of 1.8x and a peer group closer to 7.3x. That points to a premium against the typical balance sheet valuation in the industry, yet a sizeable gap to higher priced specialist peers that investors may be using as comps for late stage pipelines.

Because the recent uveal melanoma drug application and Phase 3 planning have lifted expectations around IDEAYA Biosciences, the stock now prices in a richer claim on its equity base than the wider group, while still sitting below the level at which the more aggressively valued biotechs trade. This leaves the current P/B multiple sending a clear message that optimism around the clinical story already feeds into the share price, and that any further upside case rests on how much value you think those trials and regulatory milestones can add to the book over time. Explore the numbers behind IDEAYA Biosciences's P/B valuation.

NasdaqGS:IDYA P/B Ratio as at Nov 2026
NasdaqGS:IDYA P/B Ratio as at Nov 2026

The IDEAYA Biosciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for IDEAYA Biosciences pick up directly from that price to book puzzle and outline which paths for revenue, margins and earnings would need to occur for the shares to be worth materially more or materially less than today. Each scenario assigns a fair value estimate to a specific mix of potential catalysts and risks, so you can monitor over time which version of IDEAYA Biosciences' story appears to be playing out on the Community page.

One of the top narratives on IDEAYA Biosciences: 10% undervalued

This Narrative is the bearish analyst Narrative on Simply Wall St, built on the most pessimistic analyst price target and forecasts, not one person's view.

"The June 2026 equity raise of about US$345 million in gross proceeds, which increased the share count, could dilute per share participation in any future revenue…"

Discover why this Narrative puts IDEAYA Biosciences at 10% undervalued.

One last IDEAYA Biosciences check that sits outside the valuation ratios

Price to book tells only part of the IDEAYA Biosciences story, since Simply Wall St’s broader review has also flagged specific risk checks that deserve your attention before you lean too hard on the multiples alone. Take a closer look at 1 warning sign before settling on a valuation.